Supply of carmustine (BiCNU) 100 mg powder for injection vial with diluent vial by Watson Pharma Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply and use of therapeutic goods in Australia, aiming to ensure their safety, quality, and efficacy. The Act provides a comprehensive framework for the regulation of therapeutic goods, including medicines, medical devices, and blood and blood components. The Therapeutic Goods Administration (TGA) is the key agency responsible for administering the Act, and its primary policy objective is to protect public health by ensuring that only therapeutic goods that meet safety, quality, and efficacy standards are supplied in Australia. This legislation was introduced to address the need for a unified regulatory approach to the oversight of therapeutic goods, replacing previous state-based systems with a national framework. The Act empowers the TGA to take action against the supply of therapeutic goods that do not comply with the regulatory requirements, thereby safeguarding the health and well-being of the Australian population. On November 29, 2013, the delegate of the Secretary of the Department of Health granted consent for the supply of a specific batch of the product carmustine (BiCNU) 100 mg powder for injection vial with diluent vial, manufactured by Watson Pharma Pty Ltd, under subsections 14 and 14A of the Therapeutic Goods Act 1989. This consent was issued subject to certain conditions, including limitations on the number of units supplied, the use of specified US labels and carton labels, and the provision of a Dear Doctor letter and Australian product information with each order. This decision reflects the TGA's commitment to ensuring the safe and effective use of therapeutic goods in Australia, while also facilitating access to necessary medicines for patients in need.

Scope and Application

The Therapeutic Goods Act 1989, as evidenced by the Gazette C2013G01825, facilitates the regulation of therapeutic goods in Australia. This particular notice, issued under sections 14 and 14A of the Act, pertains to the specific supply of a product, carmustine (BiCNU) 100 mg powder for injection vial with diluent vial, by Watson Pharma Pty Ltd, located in Sydney. The consent given by the delegate of the Secretary of the Department of Health is subject to conditions that ensure compliance with the regulatory standards set by the Therapeutic Goods Administration. This consent is limited to a specific batch, CDDA310, encompassing 245 units, and mandates the use of particular US labels and an over-labelled carton as specified in the application. Additionally, users must receive a Dear Doctor letter and the Australian product information for BiCNU with each order. The scope of the Act extends to the regulation of therapeutic goods within Australia, ensuring their safety, quality, and efficacy. The application of the Act is national, with its provisions enforced through the Therapeutic Goods Administration under the Department of Health.

Key Provisions

The Therapeutic Goods Act 1989, specifically sections 14 and 14A, pertains to the regulation of therapeutic goods, including medicines, medical devices, and other health-related products. Section 14A provides a mechanism for the Secretary to consent to the supply of certain therapeutic goods under specific conditions, which applies to the case of the carmustine (BiCNU) 100 mg powder for injection vial with diluent vial supplied by Watson Pharma Pty Ltd. According to the notice, the delegate of the Secretary has granted consent for the supply of a specific batch (CDDA310) of this product under certain conditions (section 15(1)). Under these conditions, the supply of carmustine is limited to 245 units from the specified batch. The product must be supplied with the US labels as provided in the application, and the carton label must be over-labelled with the over-sticker included in the email dated November 29, 2013. Additionally, each order of the product must be accompanied by the Dear Doctor letter submitted with the November 29, 2013 email, along with the Australian product information (PI) for BiCNU. These requirements ensure that users are provided with accurate and comprehensive information about the product. The obligations imposed on the parties governed by this Act include strict adherence to the conditions set forth in the consent notice. Watson Pharma Pty Ltd must ensure that only the specified number of units from batch CDDA310 are supplied, and that all labelling and accompanying documentation meet the requirements outlined in the notice. Failure to comply with these conditions can lead to regulatory action and potential penalties. Breach of the conditions specified in the notice can result in civil or criminal consequences. Under the Therapeutic Goods Act 1989, offences related to the supply of therapeutic goods include supplying goods that do not meet the standards set by the Act, which can result in fines and imprisonment. The maximum penalties for such offences can be substantial, reflecting the importance of compliance with regulations designed to protect public health and safety. It is therefore crucial for entities like Watson Pharma Pty Ltd to meticulously adhere to the stipulated conditions to avoid any legal repercussions.